Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
31.67
-0.56 (-1.74%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Veracyte Employees
Veracyte had 824 employees as of December 31, 2024. The number of employees increased by 9 or 1.10% compared to the previous year.
Employees
824
Change (1Y)
9
Growth (1Y)
1.10%
Revenue / Employee
$540,976
Profits / Employee
$29,294
Market Cap
2.47B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VCYT News
- 3 days ago - Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - Business Wire
- 6 days ago - Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting - Business Wire
- 7 days ago - Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release - Business Wire
- 4 weeks ago - New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - Business Wire
- 5 weeks ago - Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - Business Wire
- 2 months ago - Solid Growth, Soft Outlook: Why I'm Holding On Veracyte - Seeking Alpha
- 2 months ago - Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive - Benzinga
- 2 months ago - Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript - Seeking Alpha